Magnetic stimulation to test whether it slows Parkinson's disease progression
Tests magnetic brain stimulation during sleep in people with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT06002581, who can take part
Where in China
- Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT06002581
- Record updated
- 9 December 2025
- Original description
At present, no drug therapy has been proven to delay the progression of Parkinson's disease (PD). rTMS, as a non-invasive neuromodulation method, can regulate Slow-wave sleep (SWS). SWS is recognized closely related to neurodegeneration. However, there has been no clinical studies on if rTMS could delay the progression of PD by regulating SWS.Read full original descriptionShow less
Clinical Study on the Efficacy and Safety of rTMS Regulating Slow-wave Sleep to Delay the Progression of Parkinson's Disease
At present, no drug therapy has been proven to delay the progression of Parkinson's disease (PD). rTMS, as a non-invasive neuromodulation method, can regulate Slow-wave sleep (SWS). SWS is recognized closely related to neurodegeneration. However, there has been no clinical studies on if rTMS could delay the progression of PD by regulating SWS.
The main purpose of this study is to explore the changes of SWS in non-rapid eye movement (NREM) sleep period in PD patients by using rTMS, and the relationship with potential improvements of SWS and motor symptom delay. The study aims to find a potential new treatment strategy to delay the neurodegenerative process in PD patients by modulating SWS by rTMS.
Inclusion: Meet the clinically definite or clinically probable PD according to the MDS 2015 version; Chinese Han population (three generations), age greater than or equal to 50 years old, less than or equal to 80 years old, male or female; Hoehn-Yahr stages 1-4; The dose of levodopa drug therapy was stable three weeks before enrollment and during the follow-up period; Right-handed; The patient signed a written informed consent.
Exclusion: Those who have received neurosurgical intervention or stereotaxic brain surgery for PD, or have previously received TMS treatment; Patients who are addicted to alcohol, taking SSRIs, TCAs, sedative hypnotics, histamine antagonists and other drugs and food that may affect NREM and REM sleep structure; Baseline PSG suggests other sleep disorders such as moderate to severe OSAS; BMI>=30; Any form of Parkinsonism other than primary PD; Cognitive dysfunction (MMSE ≤ 24 points) or those who cannot cooperate with the scale score; Persons with mental disabilities; Pregnant women; There are contraindications for rTMS treatment; There are contraindications for MRI examination; Those who are unwilling to participate in the study or unable to sign the informed consent form; and other circumstances that the researcher considers inappropriate to participate in the study; -.